Multiple Sclerosis Trial, Not Yet Recruiting NCT07128160 Sponsor: Assiut University Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Not Yet Recruiting

NCT07128160
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are 18 years of age or older.
  • People who have been diagnosed with relapsing-remitting multiple sclerosis (a type of MS with periods of symptoms followed by recovery) based on a specific set of diagnostic guidelines from 2017.
  • People whose level of physical disability, as measured by a standard MS scoring scale, falls within a certain range (confirm with trial site for exact score requirements).
  • People who have either been on a stable dose of MS medication for at least 3 months, or who have never taken MS medication before.
  • People who have not had an MS relapse or received steroid treatment in the past 3 months.
  • People who are able to give their consent to participate and complete a series of brain and thinking assessments.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have another neurological or mental health condition, such as major depression, bipolar disorder, or schizophrenia.
  • People with a history of alcohol or drug misuse.
  • People who cannot safely have an MRI scan (for example, due to a pacemaker or metal implants in the body) or a non-invasive brain stimulation procedure called TMS (for example, due to a history of seizures or metal implants in the head area).
  • People who are taking medications known to affect how signals travel through certain brain and nerve pathways.
  • People with severe vision problems, significant physical weakness, or significant difficulties with thinking and memory (as measured by a standard cognitive screening test).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 November 2026

Primary endpoints

Motor Evoked Potential (MEP); Cortical Silent Period (CSP); Interhemispheric Inhibition (IHI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov